IFNB;Interleukin HP;Interferon Beta;B-Cell Stimulatory Factor;IFN-Beta;B-cell hybridoma growth factor;B-Cell Stimulatory Factor 2;BSF2;BSF-2;CDF;CTL Differentiation Factor;HGF;HSF;Hybridoma Growth Factor;IFN-Beta-2;IL-6;Interferon Beta-2;Interleukin 6;Interleukin HP-1;Interleukin-6;IL6;IFNB2;B cell differentiation factor;B cell stimulatory factor 2;BSF 2;Hepatocyte stimulatory factor;Hybridoma growth factor Interferon beta-2;IL 6;Interferon beta 2;Interleukin 6 (interferon beta 2);Interleukin BSF 2;Interleukin-6;IL-6;B-cell hybridoma growth factor;Interleukin HP-1

CHO cells

Val30-Met212

P05231

Human

45 kDa

45-55 kDa

C-Fc

Measured in a cell proliferation assay using TF-1 human erythroleukemic cells. The ED50 for this effect is 0.02 ng/mL.

> 90% as determined by reducing SDS-PAGE.

< 1.0 EU/mg of the protein as determined by the LAL method

Lyophilized protein should be stored at < -20℃, Reconstituted protein solution can be stored at 4-7℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months.

This product is provided as lyophilized powder which is shipped with ice packs.

Lyophilized from a 0.2 μm filtered solution in PBS with 5% Trehalose and 5% Mannitol.

It is recommended that sterile water be added to the vial to prepare a stock solution of 0.5 mg/mL. Concentration is measured by UV-Vis.

Interleukin-6 (IL-6) is a pleiotropic, alpha-helical, 22-28 kDa phosphorylated and variably glycosylated cytokine that plays important roles in the acute phase reaction, inflammation, hematopoiesis, bone metabolism, and cancer progression. IL-6 induces signaling through a cell surface heterodimeric receptor complex composed of a ligand binding subunit (IL-6 R alpha) and a signal transducing subunit (gp130). IL-6 binds to IL-6 R alpha, triggering IL-6 R alpha association with gp130 and gp130 dimerization. Soluble forms of IL-6 R alpha are generated by both alternative splicing and proteolytic cleavage. In a mechanism known as trans-signaling, complexes of soluble IL-6 and IL-6 R alpha elicit responses from gp130-expressing cells that lack cell surface IL-6 R alpha. Trans-signaling enables a wider range of cell types to respond to IL-6, as the expression of gp130 is ubiquitous, while that of IL-6 R alpha is predominantly restricted to hepatocytes, monocytes, and resting lymphocytes. Soluble splice forms of gp130 block trans-signaling from IL-6/IL-6 R alpha but not from other cytokines that use gp130 as a co-receptor. IL-6, along with TNF-alpha and IL-1, drives the acute inflammatory response and the transition from acute inflammation to either acquired immunity or chronic inflammatory disease. When dysregulated, it contributes to chronic inflammation in obesity, insulin resistance, inflammatory bowel disease, arthritis, sepsis, and atherosclerosis. IL-6 can also function as an anti-inflammatory molecule, as in skeletal muscle where it is secreted in response to exercise.